Drug eluting stents remain a “major concern” in the longer term, finds studyBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b253 (Published 22 January 2009) Cite this as: BMJ 2009;338:b253
- David Spurgeon
A three year Canadian study of more than 6000 patients who had an angioplasty with either drug eluting or bare metal stents concludes that the medicated version, now used in 85% of procedures in the United States and in 40% or more elsewhere, could be associated with longer term adverse events (CMAJ 2009;180:167-74, doi:10.1503/cmaj.080050).
An accompanying commentary, from Columbia University Medical Centre, New York, notes that “despite the large and favourable long-term data on the use of drug-eluting stents from randomised controlled trials, meta-analyses and observational studies, the long-term safety of drug-eluting stents, especially regarding late and very late stent thrombosis, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial